Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

 
• By Jessica Merrill

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.

text 10 percentages discount 3d red white banner, letters and block, business concept
Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock

More from New Products

More from Scrip